386 related articles for article (PubMed ID: 32805498)
1. Radiomics and "radi-…omics" in cancer immunotherapy: a guide for clinicians.
Porcu M; Solinas C; Mannelli L; Micheletti G; Lambertini M; Willard-Gallo K; Neri E; Flanders AE; Saba L
Crit Rev Oncol Hematol; 2020 Oct; 154():103068. PubMed ID: 32805498
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence.
Kim N; Lee ES; Won SE; Yang M; Lee AJ; Shin Y; Ko Y; Pyo J; Park HJ; Kim KW
Korean J Radiol; 2022 Nov; 23(11):1089-1101. PubMed ID: 36098343
[TBL] [Abstract][Full Text] [Related]
3. Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.
Kang CY; Duarte SE; Kim HS; Kim E; Park J; Lee AD; Kim Y; Kim L; Cho S; Oh Y; Gim G; Park I; Lee D; Abazeed M; Velichko YS; Chae YK
Oncologist; 2022 Jun; 27(6):e471-e483. PubMed ID: 35348765
[TBL] [Abstract][Full Text] [Related]
4. Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.
Zhou H; Luo Q; Wu W; Li N; Yang C; Zou L
Front Immunol; 2023; 14():1088874. PubMed ID: 36936913
[TBL] [Abstract][Full Text] [Related]
5. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.
Wu M; Zhang Y; Zhang Y; Liu Y; Wu M; Ye Z
Radiol Imaging Cancer; 2019 Nov; 1(2):e190031. PubMed ID: 33778682
[TBL] [Abstract][Full Text] [Related]
6. Radiomics: an Introductory Guide to What It May Foretell.
Nougaret S; Tibermacine H; Tardieu M; Sala E
Curr Oncol Rep; 2019 Jun; 21(8):70. PubMed ID: 31240403
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
Du Y; Qi Y; Jin Z; Tian J
Cancer Lett; 2019 Dec; 466():13-22. PubMed ID: 31499119
[TBL] [Abstract][Full Text] [Related]
8. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
9. Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.
Dercle L; McGale J; Sun S; Marabelle A; Yeh R; Deutsch E; Mokrane FZ; Farwell M; Ammari S; Schoder H; Zhao B; Schwartz LH
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36180071
[TBL] [Abstract][Full Text] [Related]
10. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
11. Assessing Immunotherapy with Functional and Molecular Imaging and Radiomics.
García-Figueiras R; Baleato-González S; Luna A; Muñoz-Iglesias J; Oleaga L; Vallejo Casas JA; Martín-Noguerol T; Broncano J; Areses MC; Vilanova JC
Radiographics; 2020; 40(7):1987-2010. PubMed ID: 33035135
[TBL] [Abstract][Full Text] [Related]
12. Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.
Wu J; Mayer AT; Li R
Semin Cancer Biol; 2022 Sep; 84():310-328. PubMed ID: 33290844
[TBL] [Abstract][Full Text] [Related]
13. The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy.
Banna GL; Olivier T; Rundo F; Malapelle U; Fraggetta F; Libra M; Addeo A
Front Med (Lausanne); 2019; 6():172. PubMed ID: 31417906
[TBL] [Abstract][Full Text] [Related]
14. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
16. Radiomic Models Predict Tumor Microenvironment Using Artificial Intelligence-the Novel Biomarkers in Breast Cancer Immune Microenvironment.
Lin G; Wang X; Ye H; Cao W
Technol Cancer Res Treat; 2023; 22():15330338231218227. PubMed ID: 38111330
[TBL] [Abstract][Full Text] [Related]
17. The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.
Crombé A; Roulleau-Dugage M; Italiano A
Cancer Commun (Lond); 2022 Dec; 42(12):1288-1313. PubMed ID: 36260064
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy efficacy and machine learning.
Fang Y; Chen X; Cao C
Expert Rev Anticancer Ther; 2024; 24(1-2):21-28. PubMed ID: 38288663
[TBL] [Abstract][Full Text] [Related]
19. [Computational medical imaging (radiomics) and potential for immuno-oncology].
Sun R; Limkin EJ; Dercle L; Reuzé S; Zacharaki EI; Chargari C; Schernberg A; Dirand AS; Alexis A; Paragios N; Deutsch É; Ferté C; Robert C
Cancer Radiother; 2017 Oct; 21(6-7):648-654. PubMed ID: 28865968
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
